VisMederi announces the signing of a Memorandum of Understanding with Global Clinical Central Lab, an international company specializing in clinical trial services, at the World Vaccine Congress 2026, one of the leading global events dedicated to the vaccine sector.
The signing of the agreement represents a significant step in strengthening VisMederi’s international presence and in building a platform for collaboration between Europe and the Asia-Pacific (APAC) region. The agreement was established with the aim of developing concrete synergies in the field of vaccine development, leveraging the analytical expertise and global networks of both companies.
Through this collaboration, VisMederi and GCCL intend to expand their support for global vaccine development programs, with a particular focus on emerging infectious diseases and potential large-scale epidemic situations.
The integration of their respective BL2–3 research infrastructures and bioanalytical expertise will further strengthen their capacity to respond to complex scenarios with significant public health implications.
